Psychedelic
Era

Psilocin has a strong affinity for the 5-HT₂A receptors clustered on layer-V pyramidal neurons, the big coordinating cells of the cortex. Binding there sets off a release of BDNF (brain-derived neurotrophic factor) and switches on the TrkB pathway. Within a day of a single dose, neurons begin sprouting new dendritic branches, and animal studies have measured real jumps in synaptic density in the prefrontal cortex.

The line between self and world tends to thin out. The salience network ramps up, so ordinary things start to feel loaded with meaning, and time stops behaving. Old emotional memories surface, often softened and seen from a new angle. As the default mode network — more or less the ego's home base — quiets down, people describe a kind of oceanic openness.

It holds an FDA Breakthrough Therapy designation for treatment-resistant depression. Trials at Johns Hopkins, NYU, and Imperial College London have reported strong response rates across depression, anxiety, and addiction, often from just a couple of dosing sessions. The working theory is that it loosens rigid mental habits and gives people back some psychological flexibility.

Early work suggests that same BDNF activation might help with axonal regrowth and synaptic reorganization after a traumatic brain injury, with the sigma-1 receptor playing a supporting role in keeping neurons alive. Researchers are starting to look at post-concussive syndrome and combat TBI, and the first results are encouraging, if still preliminary.

It turns up in more than 200 species of fungi, most of them in the Psilocybe genus: P. cubensis, the Liberty Cap (P. semilanceata), P. cyanescens, and the notably potent P. azurescens. Mazatec, Zapotec, and other Mesoamerican peoples have used these mushrooms as sacrament for thousands of years.

LSD is famously indiscriminate, binding to more than two dozen receptor subtypes. Part of why it lasts so long is mechanical: a lid of the 5-HT₂A receptor folds shut over the molecule and traps it inside. It also acts on AMPA-type glutamate receptors, strengthening long-term potentiation, the cellular basis of learning and memory. And it pushes the brain into a high-entropy state that researchers have tied to creativity and flexible thinking.

It tends to be analytical and geometric, almost architectural. People talk about crystalline fractals, time losing its grip, sudden pattern recognition, and stretches of crisp logical clarity that give way to something more dissolving. Music can turn synesthetic, until you half-see it as much as hear it. More than the others, LSD gets described in terms of "cosmic consciousness," a sense of catching the underlying structure of things.

Sub-perceptual doses, somewhere in the 5–15μg range, have started to hold up in controlled settings. Placebo-controlled studies point to modest gains in cognitive flexibility, convergent thinking, and emotional regulation. What was an open secret in Silicon Valley is finally getting proper scrutiny. The likely mechanism is a light touch on 5-HT₂A that nudges thalamocortical connectivity without tipping into hallucination.

Albert Hofmann first synthesized it at Sandoz in 1938, then stumbled onto its effects in 1943. Within a couple of decades there were more than a thousand peer-reviewed papers on its therapeutic potential. Then prohibition shut the whole field down for roughly thirty years.

The body makes DMT on its own. It has been found in the pineal gland and in cerebrospinal fluid, and the enzyme that synthesizes it, INMT, shows up in cortical neurons. That raises a strange possibility: that DMT does something in ordinary brain function too, maybe in dreaming, or in that drifting hypnagogic edge just before sleep.

What makes DMT interesting beyond the trip is its grip on the Sigma-1 receptor. Sigma-1 is a chaperone protein on the endoplasmic reticulum, and it has a hand in cell survival, neuroprotection, and plasticity. Switch it on and you get more neurogenesis and neurons that hold up better under low-oxygen stress. On paper, that makes DMT a plausible candidate for stroke and TBI recovery, propping up dying cells and scaffolding new connections.

Past a certain dose, people report leaving consensus reality entirely. The usual account is of arriving in some other place altogether, populated by intelligent presences that aren't human: mechanical elves, fractal beings, geometric intelligences. What's odd is how consistent these reports are across people who share no mythology, which hints that this is a reproducible quirk of the human mind rather than something culture handed them.

Paired with the Banisteriopsis caapi vine, which carries MAOIs, DMT survives the gut and becomes orally active as ayahuasca, the brew Amazonian traditions have worked with for centuries. A ceremony runs four to six hours and tends to go deep. The early clinical data on ayahuasca for depression and PTSD is striking, and there are well-documented cases of a single ceremony shifting depressions that had lasted years.

Ketamine doesn't work the way SSRIs do. By blocking NMDA glutamate receptors it kicks off a burst of AMPA activity, and on the back of that comes a surge of BDNF. The net effect is that synaptic connections worn down by chronic stress and depression get rebuilt, and you can measure the change in hours rather than weeks. The nasal-spray form, esketamine (Spravato), was approved by the FDA in 2019.

There's a growing body of evidence for ketamine in spinal cord injury. Because it blocks NMDA receptors, it also blocks excitotoxicity, the runaway glutamate signaling that keeps killing neurons in the hours and days after an injury. In TBI models it cuts down on that secondary cell death, and through BDNF it encourages axons to sprout. Its uses in neurorehabilitation keep widening.

At high doses ketamine produces deep dissociation, a clean break from the body and the physical world. Where classic psychedelics flood the senses, the "k-hole" empties them out. People describe vast interior geometric spaces, the sense that their whole personal history has fallen away, and contact with something like pure being, or pure nothing. Strangely, a lot of them come back from that frightening dissolution describing it as healing.

MDMA-assisted psychotherapy posted some of the strongest numbers the field has seen in the Phase 3 FDA trials run by MAPS (the Multidisciplinary Association for Psychedelic Studies). After three sessions, about two-thirds of participants no longer met the criteria for a PTSD diagnosis, roughly double the placebo group. The how of it: MDMA turns down the amygdala's fear reactivity while flooding the brain with serotonin and oxytocin, opening a window in which traumatic memories can be revisited without the fear that usually shuts the process down.

MDMA doesn't bring on hallucinations the way the classic psychedelics do. What it brings instead is emotional clarity, a sudden ease with yourself, and an unusual amount of empathy for the people around you. The inner critic goes quiet. Touch and movement feel good. A lot of people describe it as meeting themselves for once without the static of shame and fear in the way, which is precisely what lets the real emotional work happen.

MDMA also drives a big release of oxytocin, the bonding hormone, and oxytocin happens to help with new learning and with reconsolidating fear memories. That opens a narrow window where a traumatic memory that had been locked in place becomes pliable again and can be re-laid with new emotional context around it. Think of it as plasticity at the level of feeling: the fear associations stored in the hippocampus and amygdala getting rewired.

Ibogaine's anti-addictive effect was found almost by accident in 1962, when Howard Lotsof noticed that a single dose had flattened his heroin withdrawal and cravings. Open-label studies since have kept reporting the same thing: one administration can interrupt opioid withdrawal within hours, and the drop in use is still measurable a year out. The leading explanation points to its long-lived metabolite, noribogaine, a serotonin reuptake inhibitor and κ-opioid agonist that may keep working on the brain's addiction circuitry for weeks after the experience itself is over.

Stanford Medicine researchers published a closely-watched prospective study in Nature Medicine (January 2024) on 30 Special Operations veterans with traumatic brain injury. Using the Magnesium–Ibogaine Stanford Traumatic Injury to the CNS protocol (MISTIC), WHODAS disability scores dropped from 30.2 at baseline to 5.1 at one month. Response rates one month post-treatment were 100% for PTSD, 97% for depression, and 93% for anxiety, with remission rates of 86%, 83%, and 83% respectively. A follow-up paper in Nature Mental Health (July 2025) analyzed EEG and MRI data showing cognitive improvements correlated with increased theta rhythms and reduced cortical complexity — the first in-human neural signature of ibogaine's therapeutic effect.

In December 2025, the Texas Health and Human Services Commission awarded $50 million to UTMB Health and UTHealth Houston to lead the IMPACT consortium (Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma) — a two-year, multicenter clinical trial spanning eleven leading Texas research institutions including UT Austin, Baylor College of Medicine, and Texas A&M. The program targets FDA approval for opioid use disorder, traumatic brain injury, and PTSD, representing the largest state-funded psychedelic research commitment in U.S. history.

Ibogaine inhibits hERG potassium channels, which can prolong the QT interval and has been associated with rare instances of fatal cardiac arrhythmia. This is the defining safety consideration in its clinical use. The Stanford MISTIC protocol's co-administration of magnesium appears to mitigate this risk — across 30 veterans receiving the combined treatment, no instances of bradycardia, tachycardia, clinically meaningful QT prolongation, or hemodynamic instability were observed. Contemporary clinical protocols require rigorous cardiac screening, continuous ECG monitoring, and medical oversight throughout the experience.

For generations the iboga root has been the sacrament of the Bwiti tradition in Gabon and Cameroon, taken in the initiation ceremonies that mark the passage into adulthood. Ibogaine gets classed as an "oneirogen," a producer of long, vivid waking dreams that look nothing like the visual geometry of the classic 5-HT₂A psychedelics. People who take it often describe a panoramic life review, old memories returning with unusual clarity and a strange emotional distance, sometimes alongside encounters with ancestral figures. Researchers suspect it's that pairing — a long introspective window plus durable shifts in craving and mood afterward — that gives the drug its therapeutic signature.